Respiri
Respiri Limited is a pioneering provider of remote healthcare solutions, focusing on respiratory health management and chronic disease management globally, especially in the US market. They develop evidence-based programs and medical devices, such as wheezo®, to support healthcare organizations, providers, and patients. Their mission is to improve health outcomes for patients with chronic diseases, including respiratory disorders, through innovative technology, clinical expertise, and customizable programs that qualify for CPT reimbursement.
Industries
Nr. of Employees
small (1-50)
Respiri
Suite 1, Level 9, 432 St Kilda Rd, Melbourne VIC 3004, Australia
Patents
Products
Breath-sensor and mobile-app system for wheeze detection
A system comprising a portable non-invasive breath sensor that records tracheal breath sounds, a mobile patient app for capture and symptom/environment logging, and a cloud portal with algorithmic wheeze detection reporting a WheezeRate for clinician review.
Breath-sensor and mobile-app system for wheeze detection
A system comprising a portable non-invasive breath sensor that records tracheal breath sounds, a mobile patient app for capture and symptom/environment logging, and a cloud portal with algorithmic wheeze detection reporting a WheezeRate for clinician review.
Services
Design and operational deployment of remote monitoring programs tailored to provider and health-plan workflows, including patient onboarding, monitoring protocols and escalation pathways.
Provision of qualified monitoring staff, exception-based reporting and assignment of a single care advocate to improve adherence and support patient self-management.
Operational billing support including coding, claims adjudication, collection and reconciliation to maximize reimbursement for remote-monitoring services.
Access to accredited providers and telehealth infrastructure for E&M and ongoing clinical oversight as part of remote programs.
Analytics service to examine CPT codes, diagnoses and utilization to identify at-risk patients, stratify populations and measure program engagement and ROI.
Customer support channels (help centre, support forms, email) for troubleshooting device connectivity, app login and recording functionality.
Design and operational deployment of remote monitoring programs tailored to provider and health-plan workflows, including patient onboarding, monitoring protocols and escalation pathways.
Provision of qualified monitoring staff, exception-based reporting and assignment of a single care advocate to improve adherence and support patient self-management.
Operational billing support including coding, claims adjudication, collection and reconciliation to maximize reimbursement for remote-monitoring services.
Access to accredited providers and telehealth infrastructure for E&M and ongoing clinical oversight as part of remote programs.
Analytics service to examine CPT codes, diagnoses and utilization to identify at-risk patients, stratify populations and measure program engagement and ROI.
Customer support channels (help centre, support forms, email) for troubleshooting device connectivity, app login and recording functionality.
Expertise Areas
- Remote Patient Monitoring (RPM) program design and deployment
- Wheeze detection and respiratory acoustic analysis
- Mobile health (mHealth) patient interfaces and data capture
- Clinical monitoring and care-advoate models for chronic disease
Key Technologies
- Tracheal breath-sound recording
- Spectrogram-based acoustic analysis
- Machine-learning wheeze detection algorithm
- Bluetooth device connectivity
News & Updates
The company has achieved new milestones in delivering wheezo® to respiratory illness patients in the US.
The company develops and integrates FDA-approved wheeze detection devices into remote healthcare programs.
Wheezo® received FDA 510(k) clearance as a Class II medical device for detecting wheeze.
The company has achieved new milestones in delivering wheezo® to respiratory illness patients in the US.
The company develops and integrates FDA-approved wheeze detection devices into remote healthcare programs.
Wheezo® received FDA 510(k) clearance as a Class II medical device for detecting wheeze.